ArticleBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2025

Biosimilar Policies and Their Impact on Market Penetration of Adalimumab, Etanercept and Infliximab: A Policy Synthesis and Descriptive Analysis in 13 OECD Countries.

Alexander C T Tam et al.PubMed ↗Publisher ↗

No numbers read from the abstract.